Friday, 23 Mar 2018

You are here

The RheumNow Week in Review - 26 May 2017

Dr. Jack Cush Reviews highlights from the past week on

  1. Study of 24 erosive RA pts shows addition of anabolic teriparatide did not significantly reduce the rate/volume of erosions
  2. Swedish study 27k+ AS, PsA and uSpA are at increased risk for Acute Coronary syndrome & stroke events
  3. β-Defensin2 is a biomarker reflects IL-17A-driven skin dz in psoriasis, not PsA. Highly correlates w/ PASI & IL-17A  Study of 8 pts controls the expression of 170 proteins in blood, nonlesional skin, and lesional skin
  4. Tight control (TC) trial in PsA (TiCOPA) shows that TC is twice costly & QALYs- not cost-effective in most analyses
  5. Claims data on 2495 JIA pts shows significantly more serious bacterial infx w/ TNFi use (HR 2.72) compared to DMARDs
  6. Among 323 ANCA-Assoc Vasculitis pts, CTX Rx(SIR 3.1) had 4.6 more cancers than RTX (SIR 0.67); RTX = pop Cancer rate
  7. Kevzara (Sarilumab) the 2nd IL-6 inhibitor approved for use in RA; priced at $39K, 30% below competition
  8. FDA approves Actemra as1st approved drug to treat Giant Cell Arteritis, based on GiACTA study.   PI says its to be given with a tapering course of steroids.
  9. ACR supports FDA draft on interchangeability, naming suffixes & Biosimilar User Fee Act; but not extrapolation- huh?
  10. Survey of 364 UK RA pts shows that giving info on TNFi helps 1/3 and scares 1/3. Many misconceptions about safety
  11. Dr Erkan says secondary THROMBOSIS prevention- Venous-rx warfarin keep INR 2-3; Arterial - warfarin keep INR 2-3 + ASA, or INR 3-4 w/o ASA
  12. Dr Forum Erkan says catastrophic antiphospholipid syndrome should be Rx with anticoagulation, steroids, IVIG w/ plasma exchange (+/- RTX)
  13. Anti-Sclerostin Drug -Romosozumab (EVENITY) Hampered by Heart Problems 
  14. Anti-IL-5 Success in Eosinophilic Granulomatosis with Polyangiitis  
  15. NLRP3 Activation in Still's Disease 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 23 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.